Gilead wins reversal of $1.2B fine in CAR-T patent fight with Bristol Myers

Thursday, a federal appeals court overturned a $1.2 billion fine on Gilead subsidiary Kite Pharma that was previously granted to Bristol Myers’ Juno Therapeutics unit and Memorial Sloan Kettering Cancer Center. The legal tussle focuses on whether Gilead’s CD19-targeted CAR-T therapy Yescarta infringed upon a Juno patent that’s licensed from MSK.